title: Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis.
abstract: OBJECTIVE
  To evaluate the immunogenicity, safety and tolerability of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis (JIA).
  
  
  METHODS
  Twenty-one patients with JIA aged 12-25 years and 21 healthy controls were enrolled and received three doses of the bivalent HPV vaccine.
  
  
  RESULTS
  All of the subjects were seronegative at baseline and seroconverted after the scheduled doses. The JIA patients showed significantly lower HPV16 neutralising antibody titres than controls 1 month after the administration of the third dose (p < 0.05), whereas no significant difference was observed in HPV18 neutralising antibody titres. Local and systemic reactions were similarly frequent in the patients and controls, and there were no significant changes in 27-joint juvenile arthritis disease activity score or laboratory tests.
  
  
  CONCLUSIONS
  The bivalent HPV vaccine is safe in patients with stable JIA and regardless of the use of medications the vaccine assures an adequate degree of protection for a certain time.
authors: Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Commenda 9, 20122 Milan, Italy.
authors: Susanna
authors: S
authors: Esposito
authors: Fabrizia
authors: F
authors: Corona
authors: Luisa
authors: L
authors: Barzon
authors: Federica
authors: F
authors: Cuoco
authors: Laura
authors: L
authors: Squarzon
authors: Giorgia
authors: G
authors: Marcati
authors: Marta
authors: M
authors: Torcoletti
authors: Monia
authors: M
authors: Gambino
authors: Giorgio
authors: G
authors: Palù
authors: Nicola
authors: N
authors: Principi
mesh_terms: D000293:Adolescent; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D001171:Arthritis, Juvenile / Q000276:immunology* / Q000473:pathology; D002648:Child; D005260:Female; D052162:Human papillomavirus 16 / Q000276:immunology; D052161:Human papillomavirus 18 / Q000276:immunology; D006801:Humans; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000009:adverse effects*; D012720:Severity of Illness Index; D055815:Young Adult
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18
keywords: HPV; autoimmune disease; bivalent papillomavirus vaccine; juvenile idiopathic arthritis; papillomavirus vaccine; rheumatological disease